Valorization

Innovation for value analyzes the use of big data and the new power it gives to patients

The conference on health innovation Innovation for value, held on November 8 in Barcelona, ​​has analyzed the opportunities offered by technological advances in the field of health. The conference, organized by the Bellvitge Biomedical Research Institute (IDIBELL) and the Platform for Innovation in Medical and Health Technologies (ITEMAS), has been attended by some of the …

Innovation for value analyzes the use of big data and the new power it gives to patients Read More »

Innovation for value, the first international innovation conference at IDIBELL

On November 8, IDIBELL and ITEMAS co-organize Innovation for Value (#I4V), a conference focusing on the opportunities offered by innovation and new technologies in the healthcare field. In this event, which will take place at the Bellvitge University Hospital, speakers will also analyze the new business opportunities that arise thanks to scientific innovation and the …

Innovation for value, the first international innovation conference at IDIBELL Read More »

New non-invasive biomarker for diagnosis and prognosis in male sterility

Researchers from the Human Molecular Genetics group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Sara Larriba, have identified a new non-invasive biomarker of the presence of sperm in the testis of azoospermic men, who represent 10% of the cases of male sterility. The work, published in the prestigious international journal Human Reproduction, …

New non-invasive biomarker for diagnosis and prognosis in male sterility Read More »

Green light to REMAB, a new IDIBELL Spin-Off

REMAB Therapeutics, the new IDIBELL Spin-off, was officially launched by the end of April 2018. The company has doctors Rafael Mañez (IP) and Daniel Bello, from the research group on innate immunity and pathology of the critical patient, as founding partners, together with IDIBELL. REMAB’s main objective is the development of a new molecule for …

Green light to REMAB, a new IDIBELL Spin-Off Read More »

Bringing research closer to the industry

IDIBELL celebrates the first edition of its Accelerator Meeting Point The Bellvitge Biomedical Research Institute (IDIBELL) held yesterday April 16th the first edition of its Accelerator Meeting Point, a meeting where CataloniaBio -association of biomedicine and health companies in Catalonia-, Biocat -institution responsible for the promotion of the life sciences and health sector in Catalonia- …

Bringing research closer to the industry Read More »

IDIBELL obtains the TECNIO certification as a public technology facilitator

The IDIBELL Business development and Innovation area, led by Raquel Egea, has obtained the TECNIO certification as a “Public Technology Facilitator”. TECNIO is the seal granted by the Generalitat de Catalunya through ACCIÓ to identify Catalan differential technology, the providers that offer it and the facilitators involved in the process of technology and knowledge transfer, …

IDIBELL obtains the TECNIO certification as a public technology facilitator Read More »

ADmit Therapeutics becomes a new IDIBELL spin-off

ADmit Therapeutics, S.L. has become a new spin-off company of Bellvitge Biomedical Research Institute (IDIBELL) after acquiring a license agreement with IDIBELL and University of Barcelona to develop a test for an early Alzheimer’s disease (AD) detection. The company is currently supported by IDIBELL, Bellvitge University Hospital (HUB) and ACCIÓ (Generalitat de Catalunya). “Our main …

ADmit Therapeutics becomes a new IDIBELL spin-off Read More »

Scroll to Top